GAP-f operates as a WHO-hosted network bringing multiple stakeholders together to tackle gaps in medicines for children. The network’s Strategic Roadmap 2025–2030 defines its shared direction. Short sentence: a clear target exists. The roadmap sets a measurable ambition described as 30 by ’30 — assess priorities across 10 high-burden diseases, accelerate 10 priority medicines and strengthen paediatric medicines ecosystems in 10 countries by 2030. The study team described this as a way to focus resources and align global action with national needs.
Progress is visible, but gaps persist. The authors noted that scientific advances and innovations must be matched by sustained investment and stronger collaboration if they are to reach children everywhere. The article from WHO framed the initiative as both strategic and operational: strategic through the roadmap and operational through concrete activities such as prioritization, research support and country-level ecosystem work.
WHO’s Paediatric Drug Optimization process (PADO) is the mechanism GAP-f uses to identify medicines and formulations that address urgent unmet needs in paediatric prevention and treatment. PADO convenes experts and partners to align priorities across disease areas. Short sentence: prioritization guides funding and research.
The output of these exercises feeds a dedicated GAP-f product portfolio. The WHO source explained that this portfolio will gather priority medicines so researchers, product developers and funders can concentrate efforts where they are most needed. The document did not list the 10 priority medicines in this summary; details on specific candidate products were not reported in the source material.
Appropriate medicines for children require evidence on safety, efficacy and practical use. GAP-f, the authors reported, is working with partners to enable and strengthen paediatric clinical research. Activities described include mapping clinical research site capacity, promoting the inclusion of children in clinical studies and supporting more efficient study designs. Short sentence: evidence generation is central.
GAP-f will provide a package of clinical research resources. The package, as described in the WHO text, compiles information on global paediatric clinical trial sites, offers guidance on paediatric clinical trial design and implementation, and presents cross-stakeholder recommendations for optimal study design. The source did not provide granular methodological details, exact tool contents, or timelines for when specific resources will be released; those details were not reported.
Developing age-appropriate formulations addresses only one barrier. The WHO authors emphasized that children must be able to access suitable products once they exist. GAP-f works with WHO technical departments, Member States and partners to identify barriers to access and to support uptake.
In May 2026, WHO and GAP-f partners convened a regional workshop focused on strengthening paediatric medicines ecosystems in the South-East Asia region. Stakeholders from four pilot countries participated. A new workshop report captures findings and outlines opportunities to strengthen national systems so global priorities and evidence can be translated into context-specific action. The source did not include a full list of the pilot countries or a detailed catalogue of workshop recommendations; interested readers are referred to the WHO report for those specifics.
By connecting global priorities to national health-system realities, the network aims to move products from development into health services and routine use. Short sentence: systems work matters.
GAP-f positions itself as a convening platform. The WHO-hosted network includes partners across industry, academia, civil society and global health institutions. The article stated that closing the paediatric medicines gap requires sustained collaboration among governments, researchers, product developers, regulators, funders and civil society. The statement is concise and direct: no single actor can deliver alone.
On World Children’s Day, GAP-f reaffirmed commitment to align priorities, strengthen partnerships and accelerate progress. The source made clear that work is ongoing and that continued action is requested from the global health community. Short sentence: momentum must be maintained.
Remaining questions and documented limitations
The WHO text reiterated progress but also identified persistent gaps without providing exhaustive operational plans or timelines. The source specified that converting scientific advances into treatments for all children will require sustained investment, stronger collaboration and continued action — but it did not report detailed funding figures, specific implementation timelines, or the complete list of priority medicines and pilot countries. Those items remain unresolved in the published summary and will require follow-up documents or reporting from GAP-f and WHO to clarify next regulatory milestones, resourcing commitments and country-level implementation plans.